Asset profile
QiShenYiQi
Botanical
Evidence outlook · results not reported
NCT04944706 · Chronic Heart Failure With Preserved Ejection Fraction
The lead study's design has limits that temper confidence (see the rationale below), and its results have not been reported. This tier describes the design, not an outcome.
NCT04944706: The study was randomized and quadruple-blinded, with two QiShenYiQi dose groups and a placebo group, and enrolled 225 participants. Its primary clinical functional endpoint was 6-minute walking distance, but whether that endpoint was met cannot be determined because results are not posted.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
65 competitors in this universe: 2 direct rivals (same mechanism and indication), 3 same-class, 60 same-indication; 42 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| QiShenYiQi: this drug | Phase 2 | Botanical | Multi-target (ginsenoside) | ||
| Shenfu Injection (Shenfu Zhusheye) | Phase 2/3 | Botanical | Multi-target (ginsenoside) | ||
| Jia Shen Tablet | Phase 2 | Botanical | Multi-target (ginsenoside) | ||
| Cerebrolysin | Phase 3 | Peptide | Multi-target (ginsenoside) | ||
| MLC901 (NeuroAiD II) | Phase 3 | Botanical | Multi-target (ginsenoside) | ||
| PM012 | Phase 2/3 | Botanical | Multi-target (ginsenoside) | ||
| Baxdrostat (Baxfendy) | Approved | Small molecule | Aldosterone synthase (CYP11B2) | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Empagliflozin (Jardiance) | Approved | Small molecule | SGLT2 | ||
| Ferric Carboxymaltose (Injectafer / Ferinject) | Approved | Iron Complex (iv) | Iron repletion | ||
| Ferric Derisomaltose (Monoferric / Monofer) | Approved | Iron Complex (iv) | Iron repletion | ||
| Finerenone (Kerendia) | Approved | Small molecule | Mineralocorticoid receptor | ||
| Furosemide (subcutaneous, scPharmaceuticals) (FUROSCIX) | Approved | Small molecule | NKCC2 | ||
| Furosemide (subcutaneous, SQ Innovation) (Lasix ONYU) | Approved | Small molecule | NKCC2 | ||
| Icodextrin (peritoneal Ultrafiltration) (Extraneal) | Approved | Device Solution (peritoneal Dialysis) | Peritoneal ultrafiltration | ||
| Isosorbide Dinitrate / Hydralazine (BiDil) | Approved | Small molecule | Hydralazine/isosorbide dinitrate (fixed combination) |
…and 50 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.